Search results
Added:
2 months ago
Source:
Arrhythmia and Electrophysiology Review
For patients with heart failure (HF) and left bundle-branch block (LBBB), left bundle-branch pacing (LBBP) has been proposed as an alternative to the standard biventricular pacing (BiVP).¹ A new randomised trial, HeartSync-LBBP, has found that LBBP leads to superior long-term clinical outcomes compared with BiVP in this patient population.²MethodologyThe HeartSync-LBBP trial was a multicentre,…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
While social determinants of health (SDOH) are known to influence outcomes in acquired cardiovascular diseases, their impact on conditions with a strong genetic basis, such as hypertrophic cardiomyopathy (HCM), has been less clear.² A new study using data from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) suggests that area-based social factors are independently associated with adverse…
View more
Added:
1 year ago
Source:
THT
THT conference has released its four late-breaking trial sessions for 2025.The fourth annual Technology and Heart Failure Therapeutics conference is set to take place from the 11th to 13th February at Omni Boston Hotel at the Seaport in Boston. Access the full programme here.Late Breaking Clinical Science Session ITuesday 11th February, 09:30 – 10:45am ESTRobotic Surgical Technique for Performing…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Sean DelaneyA significant improvement in the use of guideline-directed quadruple medical therapy (QMT) for heart failure with reduced ejection fraction (HFrEF) has been achieved through the IMPLEMENT-HF initiative, according to results published in Circulation: Heart Failure1. Over two years, participating hospitals increased the rate of defect-free QMT at discharge dramatically—from just…
View more
Added:
1 year ago
Source:
ESC Congress
The European Society of Cardiology has revealed the late-breaking science sessions to be presented at the end of August.ESC Congress 2024 will be held from the 30th August to the 2nd September at the ExCel Center in London. View the full programme here.Don't miss our video collection covering late-breaking data from ESC Congress 2024, including a preview of the most anticipated trials in View…
View more
Added:
1 year ago
Source:
ESC Congress
The European Society of Cardiology has revealed 12 Hot-Line trial sessions to be presented at the end of August.ESC Congress 2024 will be held from the 30thAugust to the 2nd September at the ExCel Center in London. View the full programme here.Don't miss our video collection covering late-breaking data from ESC Congress 2024, including a preview of the most anticipated trials in View from the…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
A novel cardiac myosin agonist, danicamtiv, has shown favourable safety and efficacy signals in patients with dilated cardiomyopathy (DCM), particularly in those with specific genetic variants, according to results from a phase 2a open-label trial.¹ Precision therapies for DCM are currently lacking, despite its diverse clinical manifestations often linked to underlying genetic causes.²Danicamtiv…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
Cardiovascular magnetic resonance (CMR) with extracellular volume (ECV) mapping can effectively track changes in cardiac amyloid burden in transthyretin amyloid cardiomyopathy (ATTR-CM) and is independently associated with patient outcomes, according to a new prospective study.¹This single-centre prospective study included 189 patients with ATTR-CM. The cohort was divided into an untreated group …
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
An exploratory analysis of the ODYSSEY-HCM trial has shown that mavacamten significantly reduces key cardiac biomarkers in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM), a condition with no approved therapies.¹ While the main trial did not meet its primary endpoints of improving functional capacity or patient-reported health status, these biomarker findings suggest a…
View more
Added:
6 months ago
Source:
Radcliffe Cardiology
New findings from a large, international registry suggest that in patients with the dual pathology of aortic stenosis and transthyretin-associated cardiac amyloidosis, a combination of aortic valve replacement and disease-specific medication offers the most significant survival benefit.¹ The study (NCT06129331) aimed to clarify the prognostic impact of these treatments in this increasingly…
View more